Alcohol Clinical and Experimental Research, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 30, 2024
Alcohol-associated hepatitis (AH) is a subtype of alcohol-associated liver disease (ALD) resulting in severe acute inflammation. This study aims to examine longitudinal trends mortality from AH the United States (US) 1999 2020, stratifying data by sex, age, and racial/ethnic groups.
Language: Английский
Cardiovascular Diabetology, Journal Year: 2024, Volume and Issue: 23(1)
Published: Sept. 28, 2024
Language: Английский
Citations
12
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 24, 2025
Language: Английский
Citations
1
Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(6), P. 217 - 221
Published: June 2, 2024
Language: Английский
Citations
4
Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown
Published: July 1, 2024
Language: Английский
Citations
4
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 27, 2025
ABSTRACT Background Steatotic liver disease (SLD), including metabolic dysfunction‐associated SLD (MASLD), has emerged as a leading cause of chronic in China. Aims We aimed to provide comprehensive and updated description prevalence Methods described the prevalence, subgroup distribution, clinical characteristics Taizhou Study Liver Diseases (T‐SOLID). Additionally, we searched for studies reporting five databases. Eligible data were analysed using generalised linear mixed model. Linear regression was applied estimate annual average percentage change (AAPC). Results Of 28,623 participants T‐SOLID, 30.8% diagnosed with SLD, among which 83.8% classified MASLD. Prevalence increased from 22.1% 2018 36.7% 2021. The meta‐analysis included 792 publications 17,404,296 subjects. Nationwide, pooled rose 23.8% (95% CI 21.9%–25.9%) during 2001–2010 27.9% (26.0%–29.8%) 2016–2023 general population (AAPC = 2.56, p < 0.0001), equating approximately 402.0 million cases. An increase observed subpopulations by region, sex, age, high‐risk groups. Northeast China had highest (35.0%). Males higher rate than females (35.0% vs. 20.6%). ranging 8.1% children adolescents 31.8% elderly. Meta‐regression identified calendar period, geographical area, residence area significant determinants prevalence. Conclusion ubiquitously rising Chinese populations underscores urgent need targeted public health interventions.
Language: Английский
Citations
0
Atherosclerosis, Journal Year: 2025, Volume and Issue: 403, P. 119161 - 119161
Published: March 7, 2025
Language: Английский
Citations
0
Metabolism and Target Organ Damage, Journal Year: 2025, Volume and Issue: 5(1)
Published: March 8, 2025
The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic (MASLD) represents a significant evolution in the nomenclature of disease. This updated terminology emphasizes dysfunction as central criterion, offering greater precision and improved risk stratification. MASLD broadens scope classification by incorporating individuals with diverse profiles, including lean patients hepatic steatosis, aligns clinical practice multifactorial nature this condition. global adoption creates opportunities for standardization research settings, facilitating multicenter collaborations enhancing development diagnostic tools therapeutic strategies. However, new poses challenges, potential confusion during implementation, cultural linguistic barriers, integration MetALD, need educational initiatives targeting healthcare providers patients. Further efforts are required refine criteria, address implementation seamlessly incorporate into international coding systems. review evaluates key advantages ongoing challenges associated MASLD, providing comprehensive analysis its impact on practice, research, health
Language: Английский
Citations
0
Liver International, Journal Year: 2025, Volume and Issue: 45(5)
Published: April 3, 2025
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated (ALD) are the major contributors to burden globally. The rise in these conditions is linked obesity, type 2 diabetes, metabolic syndrome increased alcohol consumption. MASLD ALD share risk factors, pathophysiology histological features but differ their thresholds for use, definition does not require presence of dysfunction. A recent multi‐society consensus overhauled nomenclature steatosis introduced term MetALD describe patients with dysfunction who drink more than those less ALD. This new terminology aims enhance understanding management poses challenges, such as need accurately measure consumption research clinical practice settings. Recent studies show that has significant implications patient management, it associated mortality risks severe outcomes compared alone. face progression, cancer cardiovascular disease. diagnosis involves adequate quantification use through standardised questionnaires and/or biomarkers well proper assessment stage progression using non‐invasive tools including serologic markers, imaging, elastography techniques genetic testing. Effective requires addressing both alcohol‐related factors improve outcomes. review intends provide a comprehensive overview MetALD, covering pathogenesis, potential diagnostic approaches, strategies emerging therapies.
Language: Английский
Citations
0
The American Journal of Medicine, Journal Year: 2024, Volume and Issue: 137(11), P. 1072 - 1081.e32
Published: July 22, 2024
Language: Английский
Citations
3
Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 28, 2024
Liver steatosis is a frequent finding in clinical practice and it estimated to affect 30% of the general adult population worldwide. It became one leading causes end-stage liver disease hepatocellular carcinoma. From its first description, diagnosis nonalcoholic fatty (NAFLD) required exclusion excessive alcohol consumption concomitant chronic diseases different origins, making exclusion. In recent years, need stress strict association between metabolic dysfunction (i.e., insulin resistance, overweight/obesity, type 2 diabetes, syndrome), as well desire define condition positive rather than negative way, led new definitions diagnostic criteria. Metabolic dysfunction-associated (MAFLD) was proposed by Eslam et al. 2020. More recently, Delphi consensus endorsed several international hepatologic societies terminology [metabolic steatotic (MASLD)] set The MAFLD MASLD have good degree concordance. They mainly differ number derangements needed “metabolic dysfunction” normal-weight individuals consumption. Indeed, while does not exclude patients with significant consumption, included alcohol-related (MetALD) entity, which steatosis, dysfunction, moderate intake coexist. present narrative review, we underline strengths possible limitations each definition summarize available evidence from epidemiologic studies evaluating usefulness
Language: Английский
Citations
3